Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal to Boost Cancer Treatment Options

Gilead Sciences announces acquisition of Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy anito-cel for multiple myeloma patients, with deal expected to close in Q2 2026.